Arcturus Therapeutics Ltd.

arcturusrx.com ; www.alcobra-pharma.com

Formerly Alcobra

High-Tech Company

Ceased to Operate Q1/2020

TECH VERTICALS

Biopharmaceuticals, Biotechnology, Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2008
Number of Employees	30
Reg. Number:	abCDe

DESCRIPTION

Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.

TECHNOLOGY

Arcturus has two proprietary technologies that have the potential to solve the major hurdles in RNA medicine development. Our Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) delivery platform and our unlocked nucleomonomer agent (UNA) Oligomer technology can be used together or separately to create the next-generation of safe, effective RNA medicines.

LUNAR allows systemic delivery of all types of RNA therapeutics to target tissues. UNA oligomers are more stable, more potent and less toxic than standard oligomers.

Products and Phases

Product	Phase
ADAIR (Abuse-Deterrent Amphetamine Immediate-Release )	Phase I
Alcobra is developing a proprietary Abuse-Deterrent Amphetamine Immediate-Release (ADAIR) for ADHD. ADAIR is an oral formulation of immediate-release (short-acting) dextroamphetamine that is specifically designed to limit abuse by snorting or injecting. The U.S. Department of Health and Human Services reports that nearly two million people misuse or abuse prescription stimulants annually. The ADAIR formulation was developed in close collaboration with Capsugel®, an a global leader in delivering high-quality, innovative dosage forms and solutions. Alcobra has filed patents protecting the ADAIR product drawing on discoveries made during the development process. In 2015, nearly 25 million prescriptions were filled in the U.S. for IR stimulants, which represent the fastest growing class of prescribed ADHD drugs in both the pediatric and adult segments. While effective in the treatment of ADHD, CNS stimulants have been shown in multiple studies to have high potential for abuse and addiction and are scheduled as Class II controlled substances by the U.S. Drug Enforcement Agency (DEA) and other similar agencies outside the U.S. The risks of stimulants are not limited to those who are prescribed the medications. Published studies report that between 25-60% of teenagers and college students with ADHD report being approached to give away or sell their medication. Other published studies report that 40% or more of the people who misuse stimulants, particularly immediate release stimulants, do so by snorting or injecting them.
Metadoxine Extended Release (MDX)	Phase III
Metadoxine Extended Release (MDX) is an extended-release oral formulation of metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate). Metadoxine is an ion-pair salt of pyridoxine (vitamin B6) and 2-pyrrolidone-5-carboxylate (PCA, also known as L-PGA). Metadoxine is a selective antagonist to the 5-HT2B receptor, a member of the serotonin receptor family, and does not show any binding to other serotonin receptors. Metadoxine does not bind the characterized targets of existing stimulant and non-stimulant medications (dopamine and norepinephrine receptors and transporters), and does not affect the concentration of these neurotransmitters or their metabolites in the brain. Electrophysiological studies also showed that Metadoxine caused a dose-dependent, reversible reduction in glutamatergic excitatory transmission and enhancement of GABAergic inhibitory transmission, changes that may be associated with cognitive regulation. Alcobra has completed two Phase II, placebo controlled double blind studies in adults with ADHD.
Metadoxine Extended Release (MDX) for Fragile X Syndrome	Phase III
Fragile X Syndrome, a rare disease, is the most common single-gene cause of autism and inherited cause of intellectual disability among boys. Approximately one in 4,000 males and one in 8,000 females have Fragile X Syndrome, according to the US Centers for Disease Control and Prevention (CDC). Not everyone with the mutation will show signs or symptoms of Fragile X Syndrome, and disabilities will range from mild to severe and may include intellectual disability and behavioral characteristics such as stereotypic movements (e.g., hand-flapping), problems with attention and hyperactivity and social anxiety. A majority of individuals with Fragile X Syndrome will have either Autism Spectrum Disorder or autistic symptoms, and will have varying levels of cognitive impairment. The FDA has not approved any drugs specifically for the treatment of Fragile X Syndrome or its symptoms. Because of the lack of an approved treatment for Fragile X Syndrome, there is substantial unmet medical need.
Metadoxine Extended Release (MDX) for Cognitive Impairment	Phase II
In contrast to available treatments, MDX is a not a stimulant and shows no signs of abuse or addiction. It has a differentiated mechanism of action that targets neither dopamine nor norepinephrine. The two Phase II placebo-controlled studies showed significant clinical improvement in clinical symptoms with high response rates and a rapid onset of action. The trials also demonstrated favorable tolerability. Because of its unique mechanism of action and specific clinical effect on inattention and cognitive function, we believe that MDX may be useful in treating additional cognitive disorders, and we plan to evaluate MDX in one or more of these disorders.

	TARGET MARKETS
	Pharmaceutical Companies.

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm

CONTACT INFO

Expand / Collapse All

Main Address: San Diego, United States

Address	10628 Science Center Drive, Suite 200
City	San Diego
State/Province	CA
Country	United States
Zip	92121

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Ehud Gilboa	Co-Founder
Dr. Dalia Megiddo	Co-Founder	7Health (Managing Partner)
Mr. Joseph E Payne	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Former CEO, Pearl Therapeutics
abC Defghij	Board Member	Executive Vice President of Research and Development & Chief Medical Officer, Avanir Pharmaceuticals
abC Defghij	Board Member	CEO, Cheeta Labs
abC Defghij	Board Member	Director, Microwave Networks
abC Defghij	Board Member	CEO, Brosh Capital

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Nov. 15, 2015	Fourth Public Offering	NASDAQ GM	abCDe	abCDe
Jan. 11, 2015	Third Public Offering	NASDAQ GM	abCDe	abCDe
Oct. 27, 2013	Second Public Offering	NASDAQ GM	abCDe	abCDe
May. 22, 2013	IPO	NASDAQ GM	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Feb. 22, 2011

R&D

abCDe

Seed

Oct. 01, 2008

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Venture Capital Fund	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Arcturus Therapeutics

N/A

Reverse Merger

15/11/2017

N/A

Arcturus Therapeutics Inc., a private company, merged into Alcobra Ltd. Following completion of the merger, Alcobra changed its name to Arcturus Therapeutics Ltd.

Last Updated:	abCDe
IVC Number:	abCDe